https://www.selleckchem.com/pr....oducts/asciminib-abl
87% during the 1-year follow-up. Compared to non-PolyVD and IL-6 less then 2.64 pg/mL patients, patients had non-PolyVD with IL-6 ≥ 2.64 pg/mL (HR 1.245 95%CI 1.072-1.446; P less then 0.001) and PolyVD with IL-6 less then 2.64 pg/mL (HR 1.251 95%CI 1.002-1.563; P = 0.04) were associated with an increased risk of recurrent stroke during 1-year follow-up. Likewise, patients with PolyVD and IL-6 ≥ 2.64 pg/mL (HR 1.290; 95% CI 1.058-1.572; P = 0.01) had the highest risk of recurrent stroke at 1-year follow-up among groups. Conclusi
Like
Comment
Share
